The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2010-09-305649PMID 21135257PMCID PMC3056640
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The hallmarks of cancer

  2012cited by this paper
• The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo

  2010cited by this paper
• VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance

  2010cited by this paper
• Pharmacological inhibition of Axl affects smooth muscle cell functions under oxidative stress.

  2010cited by this paper
• Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.

  2010cited by this paper
• Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition

  2010cited by this paper
• R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

  2010cited by this paper
• Molecular and cellular mechanisms of CLL: novel therapeutic approaches

  2009cited by this paper
• Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis

  2009cited by this paper
• Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG

  2009cited by this paper
• Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells.

  2009cited by this paper
• Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice.

  2009cited by this paper
• The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression

  2009cited by this paper
• Src kinases as therapeutic targets for cancer

  2009cited by this paper
• Tris (Dibenzylideneacetone) Dipalladium, a N-Myristoyltransferase-1 Inhibitor, Is Effective against Melanoma Growth In vitro and In vivo

  2008cited by this paper
• Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme

  2008cited by this paper
• Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.

  2008cited by this paper
• AXL is a potential target for therapeutic intervention in breast cancer progression.

  2008cited by this paper
• Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia.

  2008cited by this paper
• Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

  2008cited by this paper
• The reactive oxygen‐driven tumor: relevance to melanoma

  2008cited by this paper
• The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

  2008cited by this paper
• Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia.

  2008cited by this paper
• Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

  2007cited by this paper
• A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

  2007cited by this paper
• The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease

  2007cited by this paper
• Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases.

  2006cited by this paper
• Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.

  2006cited by this paper
• Expression of axl in lung adenocarcinoma and correlation with tumor progression.

  2005cited by this paper
• VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance

  2005cited by this paper
• Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor

  2005cited by this paper
• Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.

  2005cited by this paper
• Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation.

  2005cited by this paper
• Ligand Recognition and Homophilic Interactions in Tyro3 STRUCTURAL INSIGHTS INTO THE Axl/Tyro3 RECEPTOR TYROSINE KINASE FAMILY*

  2004cited by this paper
• VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.

  2004cited by this paper
• Ligand Recognition and Homophilic Interactions in Tyro3

  2004cited by this paper
• Hydrogen Peroxide Activates the Gas6-Axl Pathway in Vascular Smooth Muscle Cells*

  2004cited by this paper
• Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.

  2004cited by this paper
• Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.

  2003cited by this paper
• Expression of the Proto-Oncogene Axl in Renal Cell Carcinoma

  2003cited by this paper
• Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

  2002cited by this paper
• Expression profile of tyrosine kinases in breast cancer.

  2002cited by this paper
• Clinical significance of AXL kinase family in gastric cancer.

  2002cited by this paper
• Oncogenic kinase signalling

  2001cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Biology of chronic lymphocytic leukemia.

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor and c-Src interactions in breast cancer

  2000cited by this paper
• MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation.

  1999cited by this paper
• Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.

  1998cited by this paper
• Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site

  1997cited by this paper
• Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance.

  1997cited by this paper
• An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.

  1975cited by this paper

• Next-generation cancer therapeutics: unveiling the potential of liposome-based nanoparticles through bioinformatics

  2025cites this paper
• AXL Tyrosine Kinases: A Growing Isoform Family that Promotes Cancer Pathogenesis.

  2025cites this paper
• Phosphatidylserine and Tyro3‐Axl‐Mertk Receptor Tyrosine Kinase level detection in plasma and on plasma‐derived extracellular vesicle surface in chronic lymphocytic leukemia

  2024cites this paper
• Elucidating the phosphoregulatory network of predominant phosphosite in AXL kinase: an integrative bioinformatic approach

  2024cites this paper
• Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer

  2024cites this paper
• Overview on Immunopathology of Chronic Lymphocytic Leukemia and Tumor-Associated Antigens with Therapeutic Applications

  2024cites this paper
• Aberrantly Expressed Mitochondrial Lipid Kinase, AGK Activates JAK2-Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy.

  2024cites this paper
• Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications

  2024cites this paper
• Inhibition of a new AXL isoform (AXL3) induces apoptosis of mantle cell lymphoma cells.

  2023cites this paper
• AXL/Gas6 signaling mechanisms in the hypothalamic-pituitary-gonadal axis

  2023cites this paper
• Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

  2023cites this paper
• Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1.

  2022cites this paper
• Acute Myeloid Leukemia Cells Educate Mesenchymal Stromal Cells toward an Adipogenic Differentiation Propensity with Leukemia Promotion Capabilities

  2022cites this paper
• Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells

  2022cites this paper
• Acute Myeloid Leukemia Cells Educate Mesenchymal Stromal Cells toward an Adipogenic Differentiation Propensity with Leukemia Promotion Capabilities

  2022cites this paper
• Bone Marrow-Derived AXL Tyrosine Kinase Promotes Mitogenic Crosstalk and Cardiac Allograft Vasculopathy

  2021cites this paper
• Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer

  2021cites this paper
• Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.

  2021cites this paper
• Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma

  2021cites this paper
• Mesangioproliferative Kidney Diseases and Platelet-Derived Growth Factor–Mediated AXL Phosphorylation

  2021cites this paper
• Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.

  2021cites this paper
• AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms

  2021cites this paper
• An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression

  2021cites this paper
• SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis

  2021cites this paper
• An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKI resistant cells by modulating miR-335 expression

  2021influential citation
• Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia

  2021cites this paper
• Lyn controls chemotaxis and motility of CLL cells via phosphorylation of ROR1

  2020cites this paper
• Immunological role of TAM receptors in the cancer microenvironment.

  2020cites this paper
• Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma

  2020cites this paper
• HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells

  2020influential citation
• Implications of the Receptor Tyrosine Kinase Axl in Gastric Cancer Progression

  2020cites this paper
• Post-translational modifications of the ligands: Requirement for TAM receptor activation.

  2020cites this paper
• Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies

  2020cites this paper
• Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

  2020cites this paper
• OTT_A_257606 5901..5911

  2020cites this paper
• Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies

  2019cites this paper
• In vitro Untersuchungen zur Rolle des MER-Tyrosinkinase-Rezeptors bei der Leukämie / ZNS Interaktion der akuten lymphatischen Leukämie (ALL) im Kindesalter

  2019cites this paper
• TYRO3: A potential therapeutic target in cancer

  2019cites this paper
• The Expression of Microvesicles in Leukemia: Prognostic Approaches

  2019cites this paper
• AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma

  2019influential citation
• AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

  2019cites this paper
• TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

  2019cites this paper
• DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model

  2019cites this paper
• Reciprocal Crosstalk Between YAP1/Hippo Pathway and the p53 Family Proteins: Mechanisms and Outcomes in Cancer

  2019cites this paper
• Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?

  2019cites this paper
• Apoptotic cell clearance in the tumor microenvironment: a potential cancer therapeutic target

  2019cites this paper
• Phosphatidylserine receptor-targeting therapies for the treatment of cancer

  2019cites this paper
• Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment

  2019cites this paper
• Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.

  2019cites this paper
• Male germ cells support long-term propagation of Zika virus

  2018cites this paper
• Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy

  2018cites this paper
• Axl inhibitor R428 induces apoptosis of cancer cells by blocking lysosomal acidification and recycling independent of Axl inhibition.

  2018cites this paper
• Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT‐β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2

  2018cites this paper
• Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines

  2018cites this paper
• Axl inhibitors as novel cancer therapeutic agents.

  2018cites this paper
• The role of TAM family receptors and ligands in the nervous system: From development to pathobiology

  2018cites this paper
• Microenvironnement médullaire et résistance des LAM FLT3-ITD aux inhibiteurs de tyrosine kinase : Rôle pivot du récepteur TAM AXL

  2017influential citation
• Rôles de la PI3 kinase de classe II alpha et de la PI3K de classe III, vps34, dans la production et les fonctions plaquettaires

  2017cites this paper
• Investigations of the cancer therapeutic and protective effects of warfarin-mediated inhibition of the receptor tyrosine kinase AXL

  2017cites this paper
• Vitamin K2 inhibits rat vascular smooth muscle cell calcification by restoring the Gas6/Axl/Akt anti-apoptotic pathway

  2017cites this paper
• The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor

  2017cites this paper
• Axl and Its Mediated Signaling Axis in Cancer

  2017cites this paper
• EVOLVING THERAPIES ( R BUKOWSKI , SECTION EDITOR ) Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies

  2017cites this paper
• Axl acts as a tumor suppressor by regulating LIGHT expression in T lymphoma

  2017cites this paper
• The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance

  2017cites this paper
• TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy

  2017cites this paper
• Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?

  2016cites this paper
• Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment

  2016cites this paper
• Receptor tyrosine kinases in carcinogenesis

  2016cites this paper
• Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells

  2016cites this paper
• The Receptor Tyrosine Kinase AXL in Cancer Progression

  2016cites this paper
• Dynamics of Microvesicle Generation in B Cell Chronic Lymphocytic Leukemia: Implication in Disease Progression

  2016cites this paper
• Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia

  2016cites this paper
• Role of Axl in T-Lymphocyte Survival in Salt-Dependent Hypertension

  2016cites this paper
• Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling

  2016cites this paper
• Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy.

  2016cites this paper
• Targeting the TAM Receptors in Leukemia

  2016influential citation
• 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.

  2016cites this paper
• The role of TAM receptors in brain tumour cell signalling and behaviour

  2016cites this paper
• Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

  2016cites this paper
• Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells

  2016cites this paper
• Exosomes and CAFs: partners in crime.

  2015cites this paper
• Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

  2015cites this paper
• Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?

  2015cites this paper
• Src family kinases and their role in hematological malignancies

  2015cites this paper
• Mer tyrosine kinase promotes the survival of t ( 1 ; 19 )-positive acute lymphoblastic leukemia ( ALL ) in the central nervous system ( CNS )

  2015cites this paper
• Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors

  2015influential citation
• Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS).

  2015cites this paper
• Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.

  2015cites this paper
• Patologi Targeting chronic lymphocytic leukemia cells using anti-ROR 1 monoclonal antibodies and small molecule inhibitors

  2015cites this paper
• Mer tyrosine kinase promotes the survival of t ( 1 ; 19 )-positive acute lymphoblastic leukemia ( ALL ) in the central nervous system ( CNS )

  2015cites this paper
• Exosomes and CAFs: partners in crime

  2015cites this paper
• CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib‐resistant chronic myeloid leukaemia

  2015cites this paper
• The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma

  2014cites this paper
• Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells

  2014cites this paper
• Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.

  2014cites this paper
• The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.

  2014cites this paper
• Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

  2014cites this paper
• Apoptosis-related BCL2-family members: Key players in chemotherapy.

  2014cites this paper
• Lyn regulates cytotoxicity in respiratory epithelial cells challenged by cigarette smoke extracts.

  2014cites this paper